MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 16:30:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 дек 2023 16:30:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

27 ноя 2023 16:30:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

21 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15 ноя 2023 16:45:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

10 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

10 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

06 ноя 2023 08:00:01 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

28 сен 2023 22:30:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Proposed Public Offering

28 сен 2023 16:01:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 сен 2023 16:30:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

13 сен 2023 09:10:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

11 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

08 авг 2023 08:00:01 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

17 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

30 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™

22 июн 2023 03:30:00 Источник Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Supports International NASH Day on June 8

06 июн 2023 08:00:02 Источник Nasdaq GlobeNewswire